Dr. med. Ebru Yildiz

🔍 Often Overlooked – Oesophageal Cancer Oesophageal cancer presents unique challenges, and is all too often missed in its early stages. In our latest //radar magazine interview, Frauke Fiegl, Chairwoman of DKV, discusses this important topic with Professor Dr. Arnulf Hölscher, a leading expert in oesophageal diseases. Why is early detection so crucial? The symptoms are subtle and easily ignored – but a proactive approach can make all the difference. Here are five key points highlighted in the interview: - Regular check-ups Subtle symptoms mean routine screenings are vital, especially for those with persistent heartburn. - Heartburn as a risk factor Chronic acid reflux can lead to serious changes in the oesophagus and significantly raise cancer risk. - Prevention matters Healthy eating, avoiding tobacco, and regular endoscopic exams can help reduce your risk. - Modern treatment options Minimally invasive surgery offers precise tumour removal and greatly improves the outlook for patients. - Sharing and support Patient events are a great way to connect, share experiences and learn more about living with the disease. 👉 Read the full interview here: https://lnkd.in/eTQsHZSp Let’s raise awareness together! #OesophagealCancer #EarlyDetection #Health #Prevention #DKV #ERGO

79

#Fatigue remains a major long-term issue in #cancer #survivorship as published by Volker Arndt and team at #DKFZ in the British Journal of Cancer.  Fatigue is one of the most common #late #effects of cancer. It was assumed to gradually diminish after #treatment, but new findings show it often persists or reoccurs even 5–16 years later. ⚡ Key challenges ·       Fatigue is complex: physical, cognitive, and affective dimensions differ in causes and effects ·       Contributing factors include comorbidities, depression, lifestyle (e.g. inactivity, obesity, smoking), and social factors 🧩 What this study reveals ·       In the #CAESAR #study with >6,000 survivors of breast, prostate, and colorectal cancer, about one-third reported persistent fatigue ·       Physical fatigue, in particular, was associated with up to a 2.4-fold higher mortality risk DKFZ Press Release: https://lnkd.in/epaRyP3Z 🌍 Implications & outlook: Long-term #cancer #survivors need systematic fatigue screening, even many years post-treatment. At the same time, comprehensive #survivorship #care that integrates psychosocial, physical, and medical support may improve both quality of life and survival chances. Congratulations to the authors: Melissa Thong, Daniela D., Lena Koch-Gallenkamp, Hermann Brenner, Volker Arndt and all co-authors! Photo: Adobe Stock /mg

46

1 Kommentar

HRP Research , World Health Organization , FIGO (International Federation of Gynecology and Obstetrics) & International Confederation of Midwives (ICM) have released the new WHO Consolidated Guidelines on the Prevention, Diagnosis and Treatment of Postpartum Hemorrhage (PPH) at the FIGO World Congress on the first-ever #WorldPPHDay 🎉 The aim is to raise awareness and galvanize action on preventing maternal deaths from PPH, a leading cause of maternal mortality worldwide. #EndPPH #HealthForAll #HopefulFutures Read the editorial here: https://lnkd.in/e2sb6yqZ

379

8 Kommentare

📢 The EU Health Technology Assessment (HTA) Regulation (EU 2021/2282) is now entering into force with a stepwise approach to Joint Clinical Assessments (JCA). 🔹 From January 2025, JCAs will first apply to: • Cancer medicines with a new active substance • Advanced therapy medicinal products 🔹 By 2028, orphan medicines will be included. 🔹 By 2030, all medicines within scope of the HTA Regulation will undergo JCA. This represents a major step toward harmonized evidence generation and greater collaboration across Member States, helping accelerate patient access to innovative treatments while ensuring robust clinical value assessment.

88

2 Kommentare

📢 New publication in #EJSO – AGO Breast Commission recommendations 2025 The updated recommendations of the #AGO Breast Commission (Working Group on Gynecologic Cancers) on surgical therapy in breast cancer have just been published in the European Journal of Surgical Oncology (EJSO). 🔑 Key highlights of the 2025 update: - Focus on de-escalation of #axillary #surgery - Sentinel lymph node biopsy (#SLNB) can be omitted in select low-risk patients undergoing upfront surgery - After #neoadjuvant systemic therapy (#NAST), completion axillary lymph node dissection (#ALND) is no longer recommended in cases of low-volume residual disease (ypN0 [i+] and ypN1mi) - For patients converting from cN1 to ycN0, both TAD and ALND remain valid options - Oncoplastic breast #surgery is safe and shows comparable complication rates to standard breast-conserving surgery This update incorporates evidence from recent landmark studies such as #INSEMA (#GBG75) and #SOUND, marking another important step towards personalized and less invasive breast cancer care. 🔗 Read the full open-access article here: https://lnkd.in/dyW3u34P 🔗 INSEMA trial information: https://lnkd.in/d69SDDNd GBG Forschungs GmbH #BreastCancer #BreastCancerCare #AGO #EJSO #Oncology #Surgery #ClinicalGuidelines #Research #Review

51

3 Kommentare